Quick Answer
ENDRA Life Sciences Inc. reported Operating Income Loss of -$5.76 million for the year ending 2025.
- ENDRA Life Sciences Inc. showed an increase of +46.7% in Operating Income Loss from 2024 to 2025.
- This data is from ENDRA Life Sciences Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), ENDRA Life Sciences Inc.'s Operating Income Loss has declined by 221.6%.
- Historical annual values: Fiscal year 2025: -$5.76 million | Fiscal year 2024: -$10.82 million | Fiscal year 2023: -$10.52 million | Fiscal year 2022: -$13.16 million | Fiscal year 2021: -$11.50 million | Fiscal year 2020: -$11.50 million | Fiscal year 2019: -$10.84 million | Fiscal year 2018: -$9.02 million | Fiscal year 2017: -$4.63 million | Fiscal year 2016: -$1.79 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: